S
Stephanie O. van der Woude
Researcher at University of Amsterdam
Publications - 11
Citations - 204
Stephanie O. van der Woude is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Cancer & Chemoradiotherapy. The author has an hindex of 4, co-authored 10 publications receiving 110 citations.
Papers
More filters
Journal ArticleDOI
Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
Willemieke P M Dijksterhuis,Maarten J Pruijt,Stephanie O. van der Woude,Remy Klaassen,Sophie A Kurk,Martijn G.H. van Oijen,Hanneke W. M. van Laarhoven +6 more
TL;DR: The aim of this study is to determine the impact of body composition on survival and chemotherapy toxicity in esophagogastric cancer patients treated with first‐line palliative chemotherapy.
Journal ArticleDOI
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study
Charlotte I. Stroes,Sandor Schokker,Aafke Creemers,Remco J. Molenaar,Maarten C.C.M. Hulshof,Stephanie O. van der Woude,Roel J. Bennink,Ron A. A. Mathôt,Kausilia K. Krishnadath,Cornelis J. A. Punt,Rob H.A. Verhoeven,Martijn G.H. van Oijen,Geert Jan Creemers,Grard A. P. Nieuwenhuijzen,Maurice J.C. van der Sangen,Laurens V. Beerepoot,Joos Heisterkamp,Maartje Los,Marije Slingerland,Annemieke Cats,Geke A. P. Hospers,Maarten F. Bijlsma,Maarten F. Bijlsma,Mark I. van Berge Henegouwen,Sybren L. Meijer,Hanneke W. M. van Laarhoven +25 more
TL;DR: Addition of trastuzumab and pertuzumAB to nCRT in patients with HER2-positive EAC is feasible and demonstrates potentially promising activity compared with historical controls.
Journal ArticleDOI
Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients
Remy Klaassen,Ruben T. H. M. Larue,Banafsche Mearadji,Stephanie O. van der Woude,Jaap Stoker,Philippe Lambin,Hanneke W. M. van Laarhoven +6 more
TL;DR: A CT radiomics approach shows potential in discriminating responding from non-responding liver metastases based on the pre-treatment CT scan, although further validation in an independent patient cohort is needed to validate these findings.
Journal ArticleDOI
Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis
Emil ter Veer,Jessy Joy van Kleef,Sandor Schokker,Stephanie O. van der Woude,Marety Laarman,Nadia Haj Mohammad,Mirjam A. G. Sprangers,Martijn G.H. van Oijen,Hanneke W. M. van Laarhoven +8 more
TL;DR: The prognostic and predictive factors identified in this systematic review can be used to characterise patients in clinical practice, be included in future trial designs, enrich prognostic tools and generate hypotheses to be tested in future research to promote patient-centred treatment.
Journal ArticleDOI
Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
Sandor Schokker,Stephanie O. van der Woude,Jessy Joy van Kleef,Daan J. van Zoen,Martijn G.H. van Oijen,Banafsche Mearadji,Ludo F. M. Beenen,Charlotte I. Stroes,Cynthia Waasdorp,R. Aarti Jibodh,Aafke Creemers,Sybren L. Meijer,Gerrit K. J. Hooijer,Cornelis J. A. Punt,Maarten F. Bijlsma,Hanneke W. M. van Laarhoven +15 more
TL;DR: In conclusion, albeit that the addition of nab-paclitaxel 60 mg/m2 to CapOx may be better tolerated than other taxane triplets, relevant toxicity was observed and ADAM12 is a potential biomarker to predict survival, and warrants further investigation.